UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BridgeBio Pharma’s acoramidis under the name…
Cardiovascular
-
-
ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patients
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by O’Neill and colleagues…
-
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the…
-
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851,…
-
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the investigational oral small molecule lipoprotein(a)…
-
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label expansion…
-
HMRI and Novartis Australia sign MoU to expedite medical research
The Hunter Medical Research Institute (HMRI) has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research…
-
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
The European Commission (EC) has granted marketing authorisation to BridgeBio Pharma’s selective small molecule, acoramidis, under the brand name Beyonttra,…
-
FDA approves drug application for Lupin’s heart failure therapy
The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and Valsartan…
-
Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market…
